WSJ's Take On the Week
WSJ's Take On the Week

Sep 13, 2026 · 32 min

Biotech’s rally tests the promise of cancer breakthroughs

A Breakthrough Cancer Vaccine Fueled a Biotech Rally. Can It Last?

Investors must decide whether excitement around cancer vaccines, AI and new drug platforms reflects durable growth or inflated valuations.

3 key takeaways
  1. 1Easing regulatory fears and enthusiasm for AI helped lift both major pharmaceutical companies and smaller biotechs.
  2. 2Moderna’s cancer-vaccine rally may already reflect substantial future revenue, while Revolution Medicines presents a clearer growth story.
  3. 3China’s faster drug development and uncertain clinical data are raising a new competitive and investment challenge for U.S. pharma.

Don't miss

The China discussion compares fast-following drug development with the market shock caused by DeepSeek and raises questions about a treatment that could challenge Merck’s Keytruda.

The brief

Biotech has outperformed as regulatory fears eased and investors returned to healthcare, but the rally rests on more than one story: AI, new drug platforms and defensive positioning all matter.

The discussion tests whether Moderna’s personalized cancer-vaccine excitement justifies its valuation, contrasting it with Revolution Medicines’ more legible growth path.

Pharma is moving away from mega-mergers toward smaller, targeted acquisitions, using a venture-capital-like approach to replenish pipelines while AI improves development without replacing human trials.

The GLP-1 market shows how quickly leadership can change: Novo Nordisk’s stock fell as Eli Lilly’s more powerful competing drugs gained share.

China’s advancing biotech industry could challenge U.S. drugmakers, while unresolved survival data and an accelerated Huntington’s therapy approval expose the stakes of betting on uncertain science.

What was said on this episode

18 statements · 11 positive · 3 negative · 2 mixed · 2 neutral

  1. David Waineron Trump drug-pricing agreementsPositive3:18

    Trump’s agreements ended drug tariffs and established drug-pricing regulation.

    “Eventually, in late 2025, Trump signs these agreements, starting with Albert Bourla, the CEO of Pfizer, basically declaring the whole thing over. Tariffs are off. Drug pricing regulation is agreed upon.”

    Listen at 3:18

  2. Large pharmaceutical companies are better at acquisitions than internal innovation.

    “They're no longer really good at innovating. They're really good at acquiring companies.”

    Listen at 4:06

  3. David Waineron Healthcare investmentsPositive5:28

    Capital is rotating from AI toward healthcare investments.

    “healthcare which was kind of back here partly because of policy but also partly because ai was driving all the investment now it's sort of like money is rotating back”

    Listen at 5:28

  4. David Waineron Personalized cancer vaccinesPositive6:52

    Personalized cancer vaccines target mutations identified in a patient’s tumor.

    “you're really taking the tumor and you're looking for the mutations. And then you're building a therapy based off of that to target.”

    Listen at 6:52

  5. David Waineron ModernaPositive7:23

    Moderna’s market capitalization rose from about $20 billion to $50–60 billion.

    “it added over 25 to $30 billion. It was like about a $20 billion company before the announcement. It's now a 50 to $60 billion.”

    Listen at 7:23

  6. David Waineron ModernaNegative8:58

    Moderna’s valuation already reflects substantial future drug revenue; investors should be cautious.

    “the market definitely is attributing like a huge future revenue to this drug. And so, you know, I'd be careful with that one.”

    Listen at 8:58

  7. David Waineron Revolution Medicines pancreatic cancer drugPositive9:31

    Revolution Medicines’ approved pancreatic cancer drug extends patients’ lives.

    “this drug approved that, you know, really extends people's lives.”

    Listen at 9:31

  8. Revolution Medicines could eventually reach a $100 billion valuation.

    “this company, which is already now about a $50 billion company, could be one of those biotechs that becomes that sort of Gilead or MJAN. that trades at $100 billion one day.”

    Listen at 10:04

  9. Revolution Medicines will not be acquired.

    “Revolution Medicine will not get acquired.”

    Listen at 11:22

  10. David Waineron Small biotech acquisitionsPositive12:36

    Large pharma should acquire smaller biotechs before their data produces major drugs.

    “go for those biotech companies that maybe in a year or two will give you that data that will become the next big drug.”

    Listen at 12:36

  11. David Waineron biotechMixed17:02

    Biotech is a speculative investment rather than a defensive one.

    “Biotech is more of like a speculative investment”

    Listen at 17:02

  12. David Waineron Biotech sectorPositive18:04

    Biotech should continue performing while pharmaceutical M&A remains strong.

    “as long as the M&A boom, meaning pharma companies, keep buying biotech, and this year we're on pace for one of the best years ever, you're just going to keep seeing the sector work.”

    Listen at 18:04

  13. Novo Nordisk’s stock is approximately back to its pre-Wegovy level.

    “If you look at Novo Nordistock, I think it's about where it was before Wiggovi came to the market”

    Listen at 18:50

  14. David Waineron Biotech and pharmaceutical competitionNegative19:54

    Later entrants can displace first movers with better technology or drugs.

    “A company comes right after you, and it just has a better technology. It has a slightly better drug.”

    Listen at 19:54

  15. Eli Lilly’s Mounjaro and Zepbound are more powerful than Novo Nordisk’s competing drugs.

    “Eli Lilly came up with this combination that just worked more powerfully. And that's what we see with Monjaro and Zeppat. And so Eli Lilly has just been eating Novo Nordisk's lunch.”

    Listen at 20:26

  16. David Waineron KeytrudaPositive25:31

    Keytruda is pharma’s best-selling drug, generating over $30 billion annually.

    “the best-selling drug in pharma right now is a drug called Keytruda. It's a cancer drug. It sells over $30 billion a year”

    Listen at 25:31

  17. David Waineron Chinese-linked Keytruda competitorPositive25:54

    A Chinese-linked treatment showed better cancer-patient improvement than Keytruda’s formulation alone.

    “showed better improvement to cancer patients using... the formulation that Keytruda had, but locking it in with a new target.”

    Listen at 25:54

  18. David Waineron Chinese-linked Keytruda competitorNeutral26:43

    The Chinese-linked cancer treatment lacks definitive overall-survival data.

    “We're still waiting for the critical thing, which is... overall survival. Did patients live longer? We're waiting for more data.”

    Listen at 26:43

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Weekly email

State of the Pod, every Monday

The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.

Listen to the full episode and explore every guest, topic, and moment on PodLume.